Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 13/20 | 0.43 |
| ▸ | DRD2 | P14416 | 11/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23945908 | 0.99 | DRD4 (0.44) | DRD4DRD2SIGMAR1CACNA1HTP53 | |
| SCHEMBL23945709 | 0.85 | TP53 (0.41) | DRD4DRD2SIGMAR1TP53SMN1; SMN2 | |
| SCHEMBL26018379 | 0.85 | DRD4 (0.47) | DRD4DRD2CACNA1HMEN1KMT2A | |
| SCHEMBL24765441 | 0.83 | MEN1 (0.41) | DRD4DRD2SIGMAR1TP53SMN1; SMN2 | |
| SCHEMBL21107025 | 0.83 | MEN1 (0.45) | DRD4DRD2SIGMAR1TP53SMN1; SMN2 | |
| SCHEMBL21106866 | 0.83 | MEN1 (0.41) | DRD4DRD2SIGMAR1TP53SMN1; SMN2 | |
| SCHEMBL23945511 | 0.83 | DRD4 (0.46) | DRD4DRD2CACNA1HMEN1KMT2A | |
| SCHEMBL25972108 | 0.83 | TP53 (0.40) | SIGMAR1TP53SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22856287 | 0.82 | MEN1 (0.47) | DRD4DRD2SIGMAR1TP53SMN1; SMN2 | |
| SCHEMBL21107592 | 0.82 | MEN1 (0.47) | DRD4DRD2SIGMAR1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11723980-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11723980-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DRD4 4363/4885DRD2 4346/4885SIGMAR1 3199/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DRD4 4363/4885DRD2 4346/4885SIGMAR1 3199/4885 |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DRD4 4363/4885DRD2 4346/4885SIGMAR1 3199/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DRD4 4363/4885DRD2 4346/4885SIGMAR1 3199/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DRD4 4363/4885DRD2 4346/4885SIGMAR1 3199/4885 |
| US-20230144292-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DRD4 4363/4885DRD2 4346/4885SIGMAR1 3199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.